HDL-targeted therapies: progress, failures and future


Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that HDL is anti-atherogenic and that increasing HDL-C levels is a promising therapeutic strategy. However, the recent failure of three orally active, HDL-C-raising agents has… (More)
DOI: 10.1038/nrd4279


4 Figures and Tables

Slides referencing similar topics